Literature DB >> 1347754

T cell receptor gamma/delta expression on lymphocyte populations of breast cancer patients.

S M Alam1, J S Clark, V Leech, P Whitford, W D George, A M Campbell.   

Abstract

The quantitative distribution and phenotype of gamma/delta lymphocytes in the peripheral blood (PBL), tumour draining lymph node (LNL) and tumour infiltrating lymphocytes (TIL) from breast carcinoma patients were determined by one- and two-colour flow cytometry. The TCR-gamma/delta + cells generally expressed the T cell lineage antigen CD3. The proportions of such cells were variable but generally small from all the three sources. Phenotypic analysis revealed that the CD8 marker was consistently and predominantly observed on gamma/delta + CD3+ cells in the tumour infiltrate, whereas CD4 expression, while generally low, was noted on a significant percentage (median 10%) of LNL gamma/delta + lymphocytes. In both PBL and LNL the predominant gamma/delta cell population was CD4-8-.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1347754     DOI: 10.1016/0165-2478(92)90127-a

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  9 in total

1.  Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations.

Authors:  M R Hussein; H I Hassan
Journal:  J Clin Pathol       Date:  2006-09       Impact factor: 3.411

2.  Immunohistochemical study of gamma delta T cell receptor-positive cells in the capsular region of hepatocellular carcinoma: possible role in defense against expansion of carcinoma in the liver.

Authors:  K Chin; K Morise; K Kanayama; H Nagura
Journal:  J Gastroenterol       Date:  1995-06       Impact factor: 7.527

3.  Localization of T cell receptor (TCR)-gamma delta + T cells into human colorectal cancer: flow cytometric analysis of TCR-gamma delta expression in tumour-infiltrating lymphocytes.

Authors:  N Watanabe; A Hizuta; N Tanaka; K Orita
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

4.  Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer.

Authors:  Benjamin H Beck; Hyung-Gyoon Kim; Hyunki Kim; Sharon Samuel; Zhiyong Liu; Robin Shrestha; Hilary Haines; Kurt Zinn; Richard D Lopez
Journal:  Breast Cancer Res Treat       Date:  2009-09-18       Impact factor: 4.872

5.  Expression and prognostic significance of HLA class I, ICAM-1, and tumor-infiltrating lymphocytes in esophageal cancer.

Authors:  S B Hosch; A J Meyer; C Schneider; N Stoecklein; K L Prenzel; K Pantel; C E Broelsch; J R Izbicki
Journal:  J Gastrointest Surg       Date:  1997 Jul-Aug       Impact factor: 3.452

6.  Human Vγ2Vδ2 T cells limit breast cancer growth by modulating cell survival-, apoptosis-related molecules and microenvironment in tumors.

Authors:  Reeva Aggarwal; Jingwei Lu; Suman Kanji; Manjusri Das; Matthew Joseph; Maryam B Lustberg; Alo Ray; Vincent J Pompili; Charles L Shapiro; Hiranmoy Das
Journal:  Int J Cancer       Date:  2013-05-29       Impact factor: 7.396

7.  Analysis of T-cell receptor expressing lymphocytes infiltrating squamous cell carcinomas of the upper aerodigestive tract.

Authors:  P G Liavaag; A C Johannessen; R Nilsen; R Jonsson
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

8.  Different pattern of T cell receptor delta gene rearrangement in tumour-infiltrating lymphocytes and peripheral blood in patients with solid tumours.

Authors:  D Kowalczyk; W Skorupski; M Drews; J Nowak
Journal:  Cancer Immunol Immunother       Date:  1994-10       Impact factor: 6.968

9.  Impact of diffusion barriers to small cytotoxic molecules on the efficacy of immunotherapy in breast cancer.

Authors:  Hiranmoy Das; Zhihui Wang; M Khalid Khan Niazi; Reeva Aggarwal; Jingwei Lu; Suman Kanji; Manjusri Das; Matthew Joseph; Metin Gurcan; Vittorio Cristini
Journal:  PLoS One       Date:  2013-04-19       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.